亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        聲稱可延緩阿爾茨海默病進程的藥物獲FDA批準

        2023-10-02 23:26:55胡靜
        求學·理科版 2023年18期
        關鍵詞:胡靜肌萎縮阿爾茨海默

        胡靜

        In early July, FDA granted traditional full approval of Leqembi for the treatment of Alzheimers disease (AD). This is the first approved medication proven to slow the progression of ADs clinical symptoms. A phase three trial among 50- to 90-year-old patients with early AD showed that it can do so by about 27% over an 18-month period. While we cannot extrapolate(推斷) beyond 18 months, this represents about a six-month delay in progression of AD symptoms.

        A second disease-slowing drug, donanemab, has recently shown similar effects and may get FDA approval by the end of the year. The development of Leqembi is a notable success for medical science in that a disease previously impervious to any disease-modifying medical intervention now has an available, effective treatment. However, paraphrasing Winston Churchill, this is not the beginning of the end but the end of the beginning. The drug does not reverse disease symptoms or prevent progression, it slows progression. And there are considerations that make it inappropriate for many patients with AD. It does, however, lay the groundwork for future AD medications that could alleviate(減輕) suffering from this devastating disease for generations to come.

        An important factor for new drugs is their cost. Leqembis price tag is $26,500 per year—much more than the current symptomatic medications for AD but comparable or less expensive than new medications for other conditions, for example multiple sclerosis or ALS.

        Medicare has announced that it will provide coverage for this medication, although it is requiring that physicians perform certain clinical measures and enter the patients data in a registry in order for the drug to be covered, which will increase physician and patient burdens. Whats more, traditional Medicare only covers 80% of outpatient costs, so for those patients without supplemental insurance, a 20% copay for the drug and required MRI scans(核磁共振掃描) might amount to up to $10,000 or more per year out of pocket, but still only a fraction of the cost of a year of in a nursing home.

        (材料來自CNN網站,有刪改)

        1. What can we learn from the first two paragraphs?

        A. Leqembi can make a six-month delay of ADs symptoms over a two-year period.

        B. To some degree, Leqembi is effective to slow the progression of AD symptoms.

        C. Both donanemab and Leqembi have got FDA approval.

        D. The drug is appropriate for any patient with AD.

        2. The underlined sentence in Paragraph 2 means _____ in the passage.

        A. although the new drug has undergone trials, it is still not effective enough

        B. though Leqembi is proven to slow the progression of ADs symptoms, we still have a long way to go

        C. the research of the Leqembi will come to an end

        D. some others problems related to the the medicine have been caused

        3. Leqembis price is _____ according to the passage.

        A. much cheaper than other medications for AD

        B. much more than current medications for other conditions

        C. affordable to almost every patient

        D. cheaper than new medications for ALS

        4. Medicare will provide coverage for this medication on condition that _____.

        A. physician and patient burdens are increased

        B. patients do not have supplemental insurance

        C. patients data is registered and clinical measures are carried out by doctors

        D. patients pay the cost of a year of in a nursing home

        1. B。解析:細節(jié)理解題。根據(jù)材料第一段中的實驗結果和第二段中的“The drug does not reverse disease symptoms or prevent progression, it slows progression.”,我們可知這種藥物不能逆轉疾病癥狀或阻止病情發(fā)展,但它可以減緩病情進展。故選B。

        2. B。解析:句意猜測題。根據(jù)材料第二段中的“And there are considerations that make it inappropriate for many patients with AD. It does, however, lay the groundwork for future AD medications that could alleviate suffering from this devastating disease for generations to come.”,我們可知雖然Leqembi這一藥物能起到延緩病情的效果,但是目前其仍舊存在局限性。故選B。

        3. D。解析:細節(jié)理解題。材料第三段提到:使用Leqembi的話,每年需花費26500美元,費用遠遠超過目前的對癥藥物,但這一費用與治療其他疾病(如多發(fā)性硬化或肌萎縮側索硬化)的新藥物價格相當或是比它們更便宜。故選D。

        4. C。解析:細節(jié)理解題。根據(jù)材料最后一段中的“Medicare has announced that it will provide coverage for this medication, although it is requiring that physicians perform certain clinical measures and enter the patients data in a registry in order for the drug to be covered.”,我們可知承保條件是醫(yī)生執(zhí)行某些臨床措施并錄入患者的數(shù)據(jù)。故選C。

        猜你喜歡
        胡靜肌萎縮阿爾茨海默
        2023年春節(jié),旅游業(yè)強勁復蘇
        阿爾茨海默病的預防(下)
        中老年保健(2022年2期)2022-08-24 03:21:24
        阿爾茨海默病的預防(上)
        中老年保健(2022年1期)2022-08-17 06:14:36
        Nonlinear oscillation characteristics of magnetic microbubbles under acoustic and magnetic fields
        Theoretical model and experimental investigation optically triggered hollowcathode discharge formation
        睡眠不當會增加阿爾茨海默風險
        奧秘(2018年9期)2018-09-25 03:49:56
        額顳葉癡呆伴肌萎縮側索硬化1例
        CH25H與阿爾茨海默病
        肌萎縮側索硬化癥的重復電刺激研究
        腓骨肌萎縮癥SIMPLE基因突變分析
        av在线一区二区三区不卡| 亚洲h视频| 日韩无码电影| 亚洲av色精品国产一区二区三区| 人妻诱惑中文字幕在线视频| 亚洲成在人网站av天堂| 一国产区在线观看| 最新国产av网址大全| 国产一区二区三区天堂| 边喂奶边中出的人妻| 亚洲欧美精品91| 国产美女高潮流白浆免费观看| 亚洲精品中文字幕视频色| 人人妻一区二区三区| 在线天堂中文字幕| 亚洲av一二三又爽又爽又色| 电驱蚊液可以插一晚上吗| 在线观看热码亚洲av每日更新| 一国产区在线观看| 久久综合这里只有精品| 亚洲av无码专区国产乱码4se| 熟妇高潮一区二区三区| 亚洲一区二区欧美色妞影院| 亚洲综合一区二区三区久久| 天天做天天摸天天爽天天爱 | 国产精品福利自产拍久久| 国产91第一页| 国产精品人伦一区二区三| 少妇内射兰兰久久| 国产a级午夜毛片| 久久精品久久精品中文字幕| 男女性杂交内射女bbwxz| 成人h动漫精品一区二区| 91精品亚洲一区二区三区| 青青草高中生在线视频| 18禁黄久久久aaa片| 久久精品国产亚洲婷婷| 国产精品女同av在线观看| 7m精品福利视频导航| 中文字幕不卡在线播放| 一区二区日本免费观看|